Home > 107th Congressional Bills > H.R. 829 (ih) To direct the Federal Election Commission to set uniform national standards for Federal election procedures, change the Federal election day, and for other purposes. [Introduced in House] ...

H.R. 829 (ih) To direct the Federal Election Commission to set uniform national standards for Federal election procedures, change the Federal election day, and for other purposes. [Introduced in House] ...


Google
 
Web GovRecords.org








108th CONGRESS
  1st Session
                                H. R. 828

  To amend the Federal Food, Drug, and Cosmetic Act to allow certain 
applicants for approval of a generic drug to be eligible for a 180-day 
     period of protection from competition, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                           February 13, 2003

 Mrs. McCarthy of New York (for herself, Mr. Emanuel, Ms. Norton, Mr. 
    Owens, and Mr. Israel) introduced the following bill; which was 
            referred to the Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
  To amend the Federal Food, Drug, and Cosmetic Act to allow certain 
applicants for approval of a generic drug to be eligible for a 180-day 
     period of protection from competition, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Pharmaceutical Fiscal Accountability 
Act of 2003''.

SEC. 2. FINDINGS.

    The Congress finds as follows:
            (1) Prescription drug costs continue to rise, affecting all 
        people in the United States.
            (2) Generic drugs are approved by the Food and Drug 
        Administration and offer a safe alternative to brand-name 
        drugs.
            (3) Access to generic drugs upon expiration of valid 
        pharmaceutical patents can result in a cost-effective 
        alternative to brand-name drugs.
            (4) The generic version of a drug often enters the market 
        at a cost that is 25 to 35 percent less than the cost of the 
        brand-name version of the drug, and after a few years typically 
        sells for about 50 percent of the cost of the brand-name 
        version.
            (5) Enhancing competition between generic and brand-name 
        drug manufacturers can reduce the cost of prescription drugs.

SEC. 3. 180-DAY GENERIC DRUG EXCLUSIVITY FOR CERTAIN SUBSEQUENT 
              APPLICANTS.

    Section 505(j)(5)(B) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 355(j)(5)(B)) is amended--
            (1) in clause (iv)--
                    (A) by striking ``If the application'' and 
                inserting ``Subject to clause (v), if the 
                application''; and
                    (B) by striking ``continuing'' and inserting 
                ``containing''; and
            (2) by adding at the end the following:
            ``(v) If the application contains a certification described 
        in subclause (IV) of paragraph (2)(A)(vii) for a drug, the 
        Secretary shall treat the application as the first such 
        application submitted under this subsection for that drug if 
        every person that previously submitted an application 
        containing such a certification for that drug--
                    ``(I) fails to market the drug within 60 days after 
                the Secretary approves the previously submitted 
                application;
                    ``(II) withdraws the previously submitted 
                application;
                    ``(III) changes, for any reason, the certification 
                in the previously submitted application to a 
                certification described in subclause (III) of paragraph 
                (2)(A)(vii);
                    ``(IV) in a case in which, after the date on which 
                the previous application was submitted, new patent 
                information is submitted for the drug under subsection 
                (c)(2) for a patent for which certification is required 
                under subclause (IV) of paragraph (2)(A)(vii), fails to 
                challenge the patent that is the subject of the 
                information within 60 days after the date on which the 
                patent information is submitted; or
                    ``(V) has engaged in conduct in violation of the 
                antitrust laws (as the term `antitrust laws' is defined 
                in subsection (a) of the first section of the Clayton 
                Act (15 U.S.C. 12(a)), except that such term includes 
                section 5 of the Federal Trade Commission Act (15 
                U.S.C. 45) to the extent such section 5 applies to 
                unfair methods of competition).''.

SEC. 4. NATIONAL INSTITUTES OF HEALTH; AWARDS TO DESIGNATED SMALL 
              ENTITIES FOR PHASE 1 OR 2 CLINICAL STUDIES ON DEVELOPMENT 
              OF NEW DRUGS.

    Section 402 of the Public Health Service Act (42 U.S.C. 282) is 
amended by adding at the end the following:
    ``(m)(1) The Director of NIH shall make awards of grants or 
contracts to designated small entities to support qualifying clinical 
research on the development of new drugs that, in the determination of 
such Director, have the potential to make a significant contribution to 
the prevention, diagnosis, or treatment of a disease.
    ``(2) For purposes of this subsection:
            ``(A) The term `designated small entity' means a public or 
        private entity (including a university or other educational 
        institution) meeting the following conditions:
                    ``(i) The entity has been granted an exemption 
                under section 505(i) of the Federal Food, Drug, and 
                Cosmetic Act.
                    ``(ii) Qualifying clinical research is being or 
                will be conducted pursuant to such exemption.
                    ``(iii) The Director of NIH determines that the 
                entity may lack the financial resources to complete the 
                qualifying clinical research involved unless an award 
                under paragraph (1) is made to the entity.
            ``(B) The term `qualifying clinical research', with respect 
        to a new drug, means the conduct of Phase 1 or Phase 2 studies 
        within the meaning of section 312.21 of title 21, Code of 
        Federal Regulations (or successor regulations).
    ``(3) In supporting qualifying clinical research under paragraph 
(1) for a fiscal year, the Director of NIH shall give priority to the 
development of any new drug described in such paragraph that is being 
developed for a disease for which the amount of funds for clinical 
research obligated by the National Institutes of Health for the 
preceding fiscal year is significantly less than amounts obligated by 
such Institutes for such fiscal year for clinical research on other 
diseases.
    ``(4) For the purpose of carrying out this subsection, there are 
authorized to be appropriated $750,000,000 for fiscal year 2004, and 
such sums as may be necessary for each subsequent fiscal year.''.

SEC. 5. CONTINGENT PAYMENT FOR NATIONAL INSTITUTES OF HEALTH SUPPORT 
              FOR DEVELOPMENT OF NEW DRUGS.

    Section 402 of the Public Health Service Act (42 U.S.C. 282) (as 
amended by section 4) is further amended by adding at the end the 
following:
    ``(n)(1) The Director of NIH may not award a grant or contract to 
an entity to support the development of a new drug, including any 
research related to such development, unless the entity involved agrees 
that, if the new drug with respect to which the award is made is 
approved under section 351 or under section 505 of the Federal Food, 
Drug, and Cosmetic Act, the entity will, for the effective patent 
period for which the new drug is in commercial distribution, pay to the 
Director of NIH an amount equal to 5 percent of the profits derived 
from sales of the new drug during such period. After consultation with 
such entity, the Director of NIH may establish a schedule of periodic 
payments to meet the obligation of the entity under the preceding 
sentence.
    ``(2) Payments under paragraph (1) may be made directly by the 
entity involved or by an entity that has purchased the rights to the 
new drug involved or has received a license regarding the sale of the 
new drug.
    ``(3) Subject to the availability of appropriations, amounts paid 
to the Director of NIH under this subsection are available to the 
Director to award grants and contracts for the development of new 
drugs, and such amounts may remain available until expended.''.

SEC. 6. STUDY ON EFFECTS OF FEDERAL SUPPORT FOR RESEARCH AND 
              DEVELOPMENT OF PRESCRIPTION DRUGS.

    (a) Study.--The Comptroller General of the United States shall 
conduct a study and make findings and recommendations with respect to 
the effects of Federal funding used by Federal agencies to conduct or 
support research and development of prescription drugs, on the 
following:
            (1) The overall cost of such research and development.
            (2) The pricing of prescription drugs.
    (b) Report.--Not later than 1 year after the date of the enactment 
of this Act, the Comptroller General of the United States shall submit 
to the Congress a report on the study, findings, and recommendations 
required by subsection (a).

SEC. 7. STUDY ON PHARMACEUTICAL PATENT EXTENSIONS AND MARKET 
              EXCLUSIVITY PERIODS.

    (a) Study.--The Comptroller General of the United States shall 
conduct a study and make findings and recommendations on pharmaceutical 
patent extensions and market exclusivity periods under Federal law, 
including the effect of such extensions and periods on possible delays 
in the introduction of generic versions of prescription drugs.
    (b) Report.--Not later than 1 year after the date of the enactment 
of this Act, the Comptroller General of the United States shall submit 
to the Congress a report on the study, findings, and recommendations 
required by subsection (a).
                                 <all>

Pages: 1

Other Popular 107th Congressional Bills Documents:

1 S. 43 (is) To amend title 10, United States Code, to authorize certain disabled former prisoners of war to use Department of Defense commissary and exchange stores. [Introduced in Senate] ...
2 H.R. 1158 (ih) To establish the National Homeland Security Agency. [Introduced in House] ...
3 S. 27 (rfh) To amend the Federal Election Campaign Act of 1971 to provide bipartisan campaign reform. [Referred in House] ...
4 S. 657 (is) To authorize funding for the National 4-H Program Centennial Initiative. [Introduced in Senate] ...
5 S.Res. 82 (ats) To authorize the production of records by the Permanent Subcommittee on Investigations of the Committee on Governmental Affairs and representation by the Senate Legal Counsel. [Agreed to Senate] ...
6 H.R. 1728 (ih) To amend the Internal Revenue Code of 1986 to repeal the personal holding company tax. [Introduced in House] ...
7 H.Con.Res. 109 (rfs) Honoring the services and sacrifices of the United States merchant marine. [Referred in Senate] ...
8 S.J.Res. 5 (is) Providing for the appointment of Walter E. Massey as a citizen regent of the Board of Regents of the Smithsonian Institution. [Introduced in Senate] ...
9 S.Res. 17 (rs) Congratulating President Chandrika Bandaranaike Kumaratunga and the people of the Democratic Socialist Republic of Sri Lanka on the celebration of 53 years of independence. [Reported in Senate] ...
10 S. 479 (is) To establish a grant program administered by the Federal Election Commission for the purpose of assisting States to upgrade voting systems to use more advanced and accurate voting devices and to enhance participation by military personnel in n...
11 S. 983 (is) To suspend temporarily the duty on Fructooligosaccharides (FOS) [Introduced in Senate] ...
12 H.R. 1470 (ih) To amend titles IV and XX of the Social Security Act to restore funding [Introduced in House] ...
13 H.Res. 127 (eh) [Engrossed in House] ...
14 S. 561 (is) To provide that the same health insurance premium conversion arrangements afforded to Federal employees be made available to Federal annuitants and members and retired members of the uniformed services. [Introduced in Senate] ...
15 H.Con.Res. 69 (enr) [Enrolled bill] ...
16 H.R. 1754 (ih) To amend the Internal Revenue Code of 1986 to provide that ancestors and lineal descendants of past or present members of the Armed Forces shall be taken into account in determining whether a veterans' organization is exempt from tax. [Intr...
17 H.Con.Res. 14 (enr) [Enrolled bill] ...
18 S. 273 (is) To amend title 28, United States Code, to divide New Jersey into 2 judicial districts. [Introduced in Senate] ...
19 H.Con.Res. 149 (rds) Permitting the use of the Rotunda of the Capitol for a ceremony to present posthumously a gold medal on behalf of Congress to Charles M. Schulz. [Received in the Senate] ...
20 H.R. 448 (ih) To limit the age restrictions imposed by the Administrator of the Federal Aviation Administration for the issuance or renewal of certain airman certificates, and for other purposes. [Introduced in House] ...
21 H.Con.Res. 84 (ih) Supporting the goals of Red Ribbon Week in promoting drug-free communities. [Introduced in House] ...
22 H.R. 459 (ih) To provide for enhanced safety, public awareness, and environmental protection in pipeline transportation, and for other purposes. [Introduced in House] ...
23 H.R. 327 (ih) To amend chapter 35 of title 44, United States Code, for the purpose of [Introduced in House] ...
24 H.R. 102 (ih) To amend the Internal Revenue Code of 1986 to encourage stronger math and science programs at elementary and secondary schools. [Introduced in House] ...
25 H.R. 1699 (eh) To authorize appropriations for the Coast Guard for fiscal year 2002. [Engrossed in House] ...
26 H.R. 1066 (ih) To amend the Outer Continental Shelf Lands Act to direct the Secretary of the Interior to cease mineral leasing activity on submerged land of the Outer Continental Shelf that is adjacent to a coastal State that has declared a moratorium on...
27 H.R. 1403 (ih) To reform Federal land management activities relating to endangered species conservation. [Introduced in House] ...
28 H.R. 727 (rh) To amend the Consumer Product Safety Act to provide that low-speed electric bicycles are consumer products subject to such Act. [Reported in House] ...
29 H.R. 1376 (ih) To amend the Internal Revenue Code of 1986 to provide that transfers of family-owned business interests shall be exempt from estate taxation. [Introduced in House] ...
30 S. 478 (is) To establish and expand programs relating to engineering, science, technology, and mathematics education, and for other purposes. [Introduced in Senate] ...


Other Documents:

107th Congressional Bills Records and Documents

GovRecords.org presents information on various agencies of the United States Government. Even though all information is believed to be credible and accurate, no guarantees are made on the complete accuracy of our government records archive. Care should be taken to verify the information presented by responsible parties. Please see our reference page for congressional, presidential, and judicial branch contact information. GovRecords.org values visitor privacy. Please see the privacy page for more information.
House Rules:

104th House Rules
105th House Rules
106th House Rules

Congressional Bills:

104th Congressional Bills
105th Congressional Bills
106th Congressional Bills
107th Congressional Bills
108th Congressional Bills

Supreme Court Decisions

Supreme Court Decisions

Additional

1995 Privacy Act Documents
1997 Privacy Act Documents
1994 Unified Agenda
2004 Unified Agenda

Congressional Documents:

104th Congressional Documents
105th Congressional Documents
106th Congressional Documents
107th Congressional Documents
108th Congressional Documents

Congressional Directory:

105th Congressional Directory
106th Congressional Directory
107th Congressional Directory
108th Congressional Directory

Public Laws:

104th Congressional Public Laws
105th Congressional Public Laws
106th Congressional Public Laws
107th Congressional Public Laws
108th Congressional Public Laws

Presidential Records

1994 Presidential Documents
1995 Presidential Documents
1996 Presidential Documents
1997 Presidential Documents
1998 Presidential Documents
1999 Presidential Documents
2000 Presidential Documents
2001 Presidential Documents
2002 Presidential Documents
2003 Presidential Documents
2004 Presidential Documents

Home Executive Judicial Legislative Additional Reference About Privacy